Treace Medical Concepts, Inc.

NasdaqGS TMCI

Treace Medical Concepts, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -30.33%

Treace Medical Concepts, Inc. Net Income Margin is -30.33% for the Trailing 12 Months (TTM) ending September 30, 2024, a -14.12% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Treace Medical Concepts, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -26.57%, a 28.70% change year over year.
Treace Medical Concepts, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -37.27%, a -175.10% change year over year.
Treace Medical Concepts, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -13.55%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqGS: TMCI

Treace Medical Concepts, Inc.

CEO	Mr. John T. Treace
IPO Date	April 23, 2021
Location	United States
Headquarters	203 Fort Wade Road
Employees	516
Sector	Health Care
Industries Medical Instruments Footwear

Description

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.

Key trends

Past 5 years